Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 10.59%67.57B | 17.04%283.08B | 4.64%85.46B | 27.10%72.14B | 20.54%64.39B | 22.11%61.1B | 31.18%241.88B | 69.17%81.67B | 27.19%56.76B | 10.76%53.42B |
Cost of revenue | 10.51%59.27B | 22.67%250.51B | 6.39%76.4B | 32.82%63.64B | 30.03%56.83B | 31.50%53.63B | 41.48%204.22B | 86.01%71.82B | 36.81%47.92B | 18.36%43.7B |
Gross profit | 11.17%8.3B | -13.50%32.58B | -8.08%9.06B | -3.91%8.5B | -22.18%7.56B | -19.32%7.46B | -5.94%37.66B | 1.93%9.85B | -7.91%8.84B | -14.05%9.71B |
Operating expense | 14.12%5.66B | 14.85%21.21B | 4.36%5.58B | 16.02%5.25B | 22.67%5.42B | 18.75%4.96B | 12.76%18.47B | 28.34%5.35B | 17.45%4.53B | 6.12%4.42B |
Staff costs | ---- | 5.58%5.31B | ---- | ---- | ---- | ---- | 3.72%5.03B | ---- | ---- | ---- |
Selling and administrative expenses | ---- | 20.29%7.1B | ---- | ---- | ---- | ---- | 27.97%5.9B | ---- | ---- | ---- |
-Selling and marketing expense | ---- | 20.29%7.1B | ---- | ---- | ---- | ---- | 27.97%5.9B | ---- | ---- | ---- |
Other operating expenses | ---- | 16.78%8.8B | ---- | ---- | ---- | ---- | 8.95%7.54B | ---- | ---- | ---- |
Operating profit | 5.31%2.64B | -40.79%11.36B | -22.84%3.48B | -24.84%3.24B | -59.58%2.14B | -50.68%2.5B | -18.89%19.19B | -18.07%4.51B | -24.92%4.31B | -25.81%5.3B |
Net non-operating interest income (expenses) | -28.28%-410M | -20.51%-1.33B | -10.65%-340.25M | -12.12%-324M | -26.90%-341.39M | -36.49%-319.62M | -41.99%-1.1B | -35.02%-307.5M | -47.99%-288.98M | -42.21%-269.02M |
Non-operating interest income | 1,065.86%84M | 823.33%177.29M | 919.83%67.77M | 1,343.05%87.52M | 151.92%14.8M | 1,065.86%7.21M | --19.2M | --6.65M | 737.08%6.07M | 308.13%5.87M |
Non-operating interest expense | 51.15%494M | 34.29%1.5B | 29.88%408.01M | 39.48%411.52M | 29.57%356.18M | 39.20%326.82M | 44.47%1.12B | 38.37%314.15M | 51.84%295.04M | 44.21%274.9M |
Net investment income | 28,750.33%133M | -76.18%461K | 1.35M | 618.22%1.77M | ||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -6M | -4.97M | -2.89M | 1.92M | 0 | 0 | 0 | |||
Special income (charges) | -74.71%125M | 2,260.45%493.38M | 161.73%11.25M | -121.99%-8.86M | -480.45%-3.36M | 1,051,919.15%494.36M | -14.28%-22.84M | -188.37%-18.22M | 67.28%-3.99M | 4.78%-578K |
Less:Restructuring and mergern&acquisition | 74.79%-125M | ---495.86M | --0 | ---863K | --863K | ---495.86M | --0 | --0 | --0 | --0 |
Less:Other special charges | ---- | -89.14%2.48M | -161.73%-11.25M | 143.60%9.73M | 331.14%2.49M | 3,108.51%1.51M | 14.28%22.84M | 188.37%18.22M | -67.28%3.99M | -4.78%578K |
Other non-operating income (expenses) | -154.25%-124M | -73.85%98.89M | -125.44%-23.23M | -23.22%140.11M | -500.88%-246.57M | 434.15%228.57M | 18.53%378.09M | 3.62%91.3M | 107.66%182.49M | -47.79%61.51M |
Income before tax | -19.03%2.35B | -42.40%10.62B | -26.91%3.12B | -27.32%3.06B | -69.66%1.54B | -40.50%2.91B | -20.39%18.45B | -19.52%4.27B | -25.27%4.2B | -28.66%5.09B |
Income tax | 24.65%823M | -52.86%2.72B | -43.67%657M | -27.45%979.04M | -75.26%420.74M | -57.34%660.26M | -19.68%5.76B | -23.60%1.17B | -25.80%1.35B | -23.59%1.7B |
Net income | -31.91%1.53B | -37.65%7.91B | -20.60%2.46B | -27.26%2.08B | -66.86%1.12B | -32.69%2.25B | -20.70%12.68B | -17.87%3.1B | -25.02%2.86B | -30.96%3.39B |
Net income continuous operations | -31.87%1.53B | -37.65%7.91B | -20.60%2.46B | -27.26%2.08B | -66.86%1.12B | -32.69%2.25B | -20.70%12.68B | -17.87%3.1B | -25.02%2.86B | -30.96%3.39B |
Noncontrolling interests | 43.33%240M | 25.80%1.05B | 23.09%380.56M | 89.72%318.19M | -13.61%184.56M | 15.72%167.44M | -32.96%835.24M | 17.21%309.18M | -50.26%167.72M | -50.77%213.64M |
Net income attributable to the company | -38.02%1.29B | -42.12%6.86B | -25.44%2.08B | -34.53%1.76B | -70.47%937.87M | -34.89%2.08B | -19.67%11.85B | -20.51%2.79B | -22.56%2.69B | -29.04%3.18B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -38.02%1.29B | -42.12%6.86B | -25.44%2.08B | -34.53%1.76B | -70.47%937.87M | -34.89%2.08B | -19.67%11.85B | -20.51%2.79B | -22.56%2.69B | -29.04%3.18B |
Gross dividend payment | ||||||||||
Basic earnings per share | -37.77%82.07 | -42.07%434.89 | -25.52%131.93 | -34.62%111.55 | -70.42%59.52 | -34.64%131.89 | -23.12%750.77 | -19.77%177.13 | -21.06%170.63 | -34.67%201.21 |
Diluted earnings per share | -37.77%82.05 | -42.07%434.75 | -25.52%131.89 | -34.62%111.52 | -70.41%59.5 | -34.63%131.84 | -23.10%750.42 | -19.76%177.07 | -21.02%170.56 | -34.65%201.11 |
Dividend per share | 0 | -21.74%180 | -31.11%62 | 0 | -15.71%118 | 0 | -13.21%230 | -40.00%90 | 0 | 21.74%140 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |